GSK-3β mediates antihypertrophic effects through multiple mechanisms [9]; therefore, GSK-3β deactivation during cardiac hypertrophy might represent a potential mechanism for modulating the hypertrophic activity of cardiomyocytes. This evidence concerns the gene GSK3B and cardiac hypertrophy.